Form 4: Xeris Biopharma Director Nerissa Kreher Acquires Shares

Director Nerissa Kreher of Xeris Biopharma Holdings, Inc. acquired 33,582 shares of common stock and 37,910 stock options.

Summary

• Nerissa Kreher, a Director at Xeris Biopharma Holdings, Inc., acquired 33,582 shares of common stock on July 1, 2026.
• These shares were granted under the company's 2018 Stock Option and Incentive Plan as restricted stock units.
• The restricted stock units vest over three years, contingent on continued service as a Director.
• Additionally, Kreher acquired 37,910 stock options with an exercise price of $8, also granted under the same plan.
• These stock options also vest over three years, subject to continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents standard compensation practices for a director, indicating continued engagement and potential long-term alignment with the company's success.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The acquisition of both restricted stock units and stock options indicates a long-term incentive alignment for the director.
• The vesting schedule over three years encourages continued commitment and service to the company.

Negatives

• The acquisition of shares and options is part of a grant, not an open market purchase, which may not reflect a personal investment decision based on current market conditions.

Risks

• The vesting of restricted stock units and stock options is contingent on continued service, meaning any departure from the board would impact the realization of these awards.
• The value of the stock options is subject to market fluctuations and the company's stock performance.

Future Outlook

The future outlook is not directly addressed in this Form 4 filing, which primarily reports on changes in beneficial ownership. However, the grants of restricted stock units and stock options suggest management's expectation of continued company operations and potential stock value appreciation.

Management Comments

• The acquisition of shares and options is pursuant to a restricted stock unit grant and stock option grant under the Company's 2018 Stock Option and Incentive Plan.
• These awards shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.

Industry Context

StockSavvy.ai notes that insider grants of equity awards, such as those reported by Xeris Biopharma Holdings, are a common practice in the biopharmaceutical industry to attract, retain, and incentivize key personnel, particularly directors and executives, aligning their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The acquisition by a director can be interpreted as a positive signal of confidence, potentially influencing investor sentiment. However, as these are grants rather than open market purchases, the direct impact on share price is likely minimal.
• Employees: The incentive structure highlights the company's approach to rewarding its board members, which may indirectly influence employee morale and retention strategies.
• Management: The grants reinforce the alignment of director compensation with long-term company performance and strategic goals.

Next Steps

• Continued service by Nerissa Kreher as a Director to meet vesting conditions for restricted stock units and stock options.
• Monitoring of Xeris Biopharma Holdings' stock performance and future SEC filings for further insider transactions or corporate developments.

Key Dates

Keywords

Xeris Biopharma Holdings, XERS, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, SEC Filing, Beneficial Ownership